Edwards Lifesciences’ earnings estimates
Edwards Lifesciences (EW) will release its third-quarter earnings results on October 23. The company is expected to register adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
In the second quarter, it reported adjusted EPS of ~$1.24, representing a ~30.5% YoY rise.
The chart above compares Edwards Lifesciences’ results and analysts’ estimates over the last five quarters. Its adjusted EPS in the second quarter exceeded analysts’ estimate by ~9.1%.
For the third quarter, Edwards Lifesciences expects to register adjusted EPS in the range of $0.93–$1.03. For 2018, the company expects to register adjusted EPS of $4.60–$4.75 compared to the guidance of $4.50–$4.70 it announced during its first-quarter earnings release.
The company’s increased 2018 guidance reflects its confidence in its increasing growth prospects and its continued strong performance. Its free cash flow for 2018 is expected to be at the higher end of its guidance range of $700 million–$775 million.
Peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO) are expected to report adjusted EPS rises of 13%, 9.7%, and 10.5%, respectively, in their recently ended quarters.